Influenza H5 vaccines

Patent metadata

Field	Value
Publication number	US-10369211-B2
Application number	US-201715662358-A
Country	US
Kind code	B2
Filing date	Jul 28, 2017
Priority date	Aug 15, 2011
Publication date	Aug 6, 2019
Grant date	Aug 6, 2019

Abstract

In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively.

First claim

The invention claimed is:

1. A method for protecting an animal against a clade 2 H5N1 influenza virus infection, comprising:
administering to the animal a composition comprising (i) a crude whole cell H5 protein of a clade 1 H5N1 influenza virus, expressed in insect cells by a baculovirus based expression system, in an amount effective to induce a cross-clade protective immune response in the animal against the clade 2 H5N1 influenza virus infection, and (ii) an inactivated Newcastle disease virus;
wherein the H5 protein of the clade 1 H5N1 influenza virus comprises a polypeptide sequence that has at least 98% sequence identity to SEQ ID NO:1;
wherein the H5 protein of the clade 1 H5N1 influenza virus has amino acid 223N and modification 328K+;
wherein amino acid position numbering of the H5 protein of the clade 1 H5N1 influenza virus refers to amino acid positions as given in SEQ ID NO:2; and
wherein modification 328K+ means that a second Lysine (K+) is inserted at amino acid position 328 of the H5 protein of the clade 1 H5N1 influenza virus.

2. The method of claim 1 , wherein the H5 protein of the clade 1 H5N1 influenza virus has amino acid 94N, amino acid 120N, amino acid 155N, or any combinations thereof.

3. The method of claim 1 , wherein the H5 protein of the clade 1 H5N1 influenza virus comprises an amino acid sequence according to:
i. any one of SEQ ID NOs: 5-7;
ii. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acid clusters:
a. aa 93-95: GNF
b. aa 123-125: SDH
c. aa 128-130: SSG
d. aa 138-140: GSS
e. aa 226-228: MDF
f. aa 270-272: EVE
g. aa 309-311: NKL;

iii. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acids: 36T, 36K, 83A, 83T, 83D, 86A, 86V, 120S, 155S, 156A, 156T, 189R, 189K, 212K, 212R, 212E, 263A, or 263T; or
iv. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acids: 36T, 36K, 83A, 83T, 83D, 86A, 86V, 120S, 155S, 156A, 156T, 189R, 189K, 212K, 212R, 212E, 263A, or 263T, and modified to have at least one of the following amino acid clusters:
a. aa 93-95: GNF
b. aa 123-125: SDH
c. aa 128-130: SSG
d. aa 138-140: GSS
e. aa 226-228: MDF
f. aa 270-272: EVE
g. aa 309-311: NKL.

4. The method of claim 1 , wherein the clade 2 H5N1 influenza virus is a clade 2.2 or clade 2.3 H5N1 influenza virus.

5. The method of claim 1 , wherein the clade 2 H5N1 influenza virus is a clade 2.2.1 or clade 2.3.2 H5N1 influenza virus.

6. The method of claim 1 , wherein the clade 2 H5N1 influenza virus is of North African or Vietnamese origin.

7. The method of claim 1 , wherein the clade 2 H5N1 influenza virus comprises an H5 protein having:
i. amino acids 113D, 126H, 145(−), 156R, 160F, 167T, and 181N, wherein modification 145(−) means that amino acid position 145 is deleted;
ii. amino acids 87P, 145L, 172T, 201E, 206I, 208K, 254T, 341G, and 421K; or
iii. amino acids 145L, 172T, and 254V,
wherein amino acid position numbering of the H5 protein of the clade 2 H5N1 influenza virus refers to amino acid positions as given in SEQ ID NO:8.

8. The method of claim 1 , wherein the clade 2 H5N1 influenza virus comprises an H5 protein having at least 95% sequence identity with at least one of SEQ ID NOs: 9-46.

9. The method of claim 1 , wherein the clade 2 H5N1 influenza virus comprises an H5 protein having:
i. amino acids 87L, 113D, 126H, 145(−), 156R, 160F, 167T, and 181N;
ii. amino acids 87P, 113N, 126R, 145L, 160Y, 172T, 181H, 201E, 206I, 208K, 254T, 341G and 421K, or
iii. amino acids 87L, 113N, 126R, 145L, 156G, 160Y, 172T, 181H, and 254V,
wherein amino acid position numbering of the H5 protein of the clade 2 H5N1 influenza virus refers to amino acid positions as given in SEQ ID NO:8.

10. The method of claim 1 , wherein the inactivated Newcastle disease virus was obtained by inactivating a Newcastle disease virus comprising a RNA polynucleotide having at least 95% sequence identity with a RNA copy of SEQ ID NO: 51.

11. The method of claim 1 , wherein the inactivated Newcastle disease virus is an inactivated LaSota strain Newcastle disease virus.

12. The method of claim 1 , wherein the inactivated Newcastle disease virus was obtained by inactivation with formaldehyde, binary ethylenimine, β-propiolactone, or any combinations thereof.

13. The method of claim 1 , wherein the animal is a poultry.

14. The method of claim 1 , wherein the composition is administered as a single dose.

15. A method for protecting an animal against clade 2 H5N1 influenza virus infection, comprising:
administering to the animal a vaccine comprising (i) an H5 protein of a clade 1 H5N1 influenza virus in an amount effective to induce a cross-clade protective immune response in the animal against clade 2 H5N1 influenza virus infection, (ii) an inactivated Newcastle disease virus, and (iii) an adjuvant,
wherein the H5 protein of the clade 1 H5N1 influenza virus comprises a polypeptide sequence that has at least 98% sequence identity to SEQ ID NO:1,
wherein amino acid position numbering of the H5 protein of the clade 1 H5N1 influenza virus refers to amino acid positions as given in SEQ ID NO:2; and
wherein modification 328K+ means that a second Lysine (K+) is inserted at amino acid position 328 of the H5 protein of the clade 1 H5N1 influenza virus.

16. The method of claim 15 , wherein the adjuvant is an oil-in water emulsified adjuvant.

17. The method of claim 15 , wherein the H5 protein of the clade 1 H5N1 influenza virus has amino acid 94N, amino acid 120N, amino acid 155N, or any combinations thereof.

18. The method of claim 15 , wherein the H5 protein of the clade 1 H5N1 influenza virus comprises an amino acid sequence according to:
i. any one of SEQ ID NOs: 5-7;
ii. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acid clusters:
a. aa 93-95: GNF
b. aa 123-125: SDH
c. aa 128-130: SSG
d. aa 138-140: GSS
e. aa 226-228: MDF
f. aa 270-272: EVE
g. aa 309-311: NKL;

iii. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acids: 36T, 36K, 83A, 83T, 83D, 86A, 86V, 120S, 155S, 156A, 156T, 189R, 189K, 212K, 212R, 212E, 263A, or 263T; or
iv. any one of SEQ ID NOs: 5-7 modified to have at least one of the following amino acids: 36T, 36K, 83A, 83T, 83D, 86A, 86V, 120S, 155S, 156A, 156T, 189R, 189K, 212K, 212R, 212E, 263A, or 263T, and modified to have at least one of the following amino acid clusters:
a. aa 93-95: GNF
b. aa 123-125: SDH
c. aa 128-130: SSG
d. aa 138-140: GSS
e. aa 226-228: MDF
f. aa 270-272: EVE
g. aa 309-311: NKL.

19. The method of claim 15 , wherein the clade 2 H5N1 influenza virus is a clade 2.2 or clade 2.3 H5N1 influenza virus.

20. The method of claim 15 , wherein the clade 2 H5N1 influenza virus is a clade 2.2.1 or clade 2.3.2 H5N1 influenza virus.

21. The method of claim 15 , wherein the clade 2 H5N1 influenza virus is of North African or Vietnamese origin.

22. The method of claim 15 , wherein the clade 2 H5N1 influenza virus comprises an H5 protein having:
i. amino acids 113D, 126H, 145(−), 156R, 160F, 167T, and 181N, wherein modification 145(−) means that amino acid position 145 is deleted;
ii. amino acids 87P, 145L, 172T, 201E, 206I, 208K, 254T, 341G, and 421K; or
iii. amino acids 145L, 172T, and 254V,
wherein amino acid position numbering of the H5 protein of the clade 2 H5N1 influenza virus refers to amino acid positions as given in SEQ ID NO:8.

Assignees

• Boehringer Ingelheim Vetmedica Gmbh
• Boehringer Ingelheim Vetmedica S A De C V

Inventors

• Realpe-Quintero Mauricio
• Gonzalez-Hernandez Paulino Carlos
• Vaughn Eric

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K2039/55566

  Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title